Controlled-release dosage forms of azithromycin

Details Controlled-release dosage forms of azithromycin Controlled-release dosage forms of azithromycin

2006-09-19

2006-09-19

Dodson, Shelly A. (Department: 1616)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S400000, C424S464000, C424S468000, C424S469000, C424S489000, C424S490000, C514S029000, C514S964000

Reexamination Certificate

active

07108865

ABSTRACT:
A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.

REFERENCES:
patent: 4434153 (1984-02-01), Urquhart et al.
patent: 4474768 (1984-10-01), Bright
patent: 4517359 (1985-05-01), Kobrehel et al.
patent: 4522625 (1985-06-01), Edgre
patent: 4755385 (1988-07-01), Etienne et al.
patent: 4792448 (1988-12-01), Ranade
patent: 4851231 (1989-07-01), Urquhart et al.
patent: 4963531 (1990-10-01), Remington
patent: 4968507 (1990-11-01), Zentner et al.
patent: 5114718 (1992-05-01), Damani
patent: 5173299 (1992-12-01), Damani
patent: 5198220 (1993-03-01), Damani
patent: 5230895 (1993-07-01), Czarnecki et al.
patent: 5605889 (1997-02-01), Curatolo et al.
patent: 5705190 (1998-01-01), Broad et al.
patent: 5747058 (1998-05-01), Tipton et al.
patent: 6068859 (2000-05-01), Curatolo et al.
patent: 0080341 (1983-07-01), None
patent: 0128655 (1984-12-01), None
patent: 0109253 (1987-10-01), None
patent: 0243302 (1987-10-01), None
patent: 0298650 (1989-01-01), None
patent: 0302836 (1989-02-01), None
patent: 0307128 (1989-03-01), None
patent: 0378404 (1990-07-01), None
patent: 0429225 (1991-05-01), None
patent: 0430474 (1991-06-01), None
patent: 0582396 (1994-02-01), None
patent: 0679400 (1995-11-01), None
patent: 2066070 (1981-07-01), None
patent: 2091097 (1982-07-01), None
patent: 8902271 (1989-03-01), None
patent: 9009168 (1990-08-01), None
patent: 9101131 (1991-02-01), None
patent: 9117744 (1991-11-01), None
patent: WO 9204890 (1992-04-01), None
patent: 9400112 (1994-01-01), None
patent: 9412159 (1994-06-01), None
patent: 9509601 (1995-04-01), None
Morishita et al., Controlled Release Microspheres Based on Eudragit L100 for the Oral Administration of Erythromycin, 1991, Drug, Design and Delivery, vol. 7, pp. 309-319.
Martindale, The Extra Pharmacopoiea, 30th, The Pharm. Press, London, 1963, p. 1197.
PDR, 48th, Med. L994, N.Y. p. 1789.
The Merck Index, 11th, Merck & Co., N.Y., 1989, p. 146 Remington Pharmaceutical Science, 16thMerck Pub.
Farmacia Practica de Remington, second Spanish edition, UTEHA, Mexico, 1965, pp. 471 and 525.
Laegemiddelkataloget, Copenhagen 1992, p. 229, and p. 356.
Farmaceuten, No. 12, 1990, p. 402-405.
Hon-Leung Lee et al., “Drug Properties Influencing The Design of Sustained or Controlled Release Drug Delivery”.
Chapters 88, 90, and 91 from Remington Pharmaceutical Science, 16thMerck Pub., Co., Pennsylvania (1980), pp. 1535, 1585, 1594.
Scott Hopkins, The American Journal of Medicine, vol. 91, (Suppl 3A) Sep. 12, 1991, 3A-40S-3A-45S.
J. R. Cardinal, Plenum Publishing Corp., 1984, Drug Release From Matrix Devices.
Richard H. Drew, Pharmacotherapy, vol. 12, No. 3, 1992, pp. 162-173.
Chem. Abstr., Yoshitomi, H., et al., V 119, No. 8, p. 496, abst. No. 79946v, “Evaluation of Enteric Coated Tablet Sensitive to Pancreatic Lipase I. In Vitro Disintegration Test”.
Farmaceitisk Tidente, No. 35/36, 1988, p. 537-548.
Milap C. Nahata et al., Antimicrobial Agents and Chemotherapy, vol. 37/2, Feb. 1993, pp. 314-316.
Gazzetta Ufficiale Della Repubblica Italiana, No. 103 of May 5, 1992 along with English translation.
H. Sucker, et al, Pharmazeutische Technologie, 2ndEdition 1991, Sections 4.4.1 to 4.4.3 along with English translation.
Physician's Desk Reference, 47thEd. 1993, entry zithromax.
H. N. Nellans, et al., Abstract 518, 31stInterscience Conf. on Antimicrobial Agents and Chemotherapy, Chicago, IL, Sep. 1991.
Isao Morishita et al., Drug Design and Delivery, vol. 7, 1991, pp. 309-319.
Farmacia Practica DeRemington, Second Spanish Ed., Uteha, Mexico, 1965, Chapters 36 and 38.
Remington's Pharm Sciences, 19Ed Spanish Farmacia Practica DeRemington, p. 2228 and 2229 (translation being obtained).
Yoshitomi, et al., Chem. Pharm. Bull, 40(7), 1902-1905, 1992.
Fiese, et al., Jml of Antimicrobial Chemotherapy, 1990, 25, suppl. A. pp. 39-47.
Anie, et al., Intml Jml of Pharmaceutics, 76, 1991, pp. 183-185.
Khosla, et al., Intrnl Jrnl of Pharmaceutics, 62, 1990, pp. R9-R11.
Knutson, et al., The Am Jrnl of Gastroenterology, 1989, vol. 84, No. 10, pp. 1278-1284.
Jobin, et al., Br. J. Clin. Pharmac, 1985, 19, pp. 97S-105S.
Blankenhom, Socl. Exp. Boil. Med, 1955, 88, pp. 356-362.
Graffner, et al., Pharm Research, vol. 7, No. 1, 1990, pp. 54-58.
Fischer, et al., Pharm Research, vol. 4, No. 6, 1987, pp. 480-485.
Welling, P., 1986, ACS Monograph 185, American Chemical Society, pp. 173-178.
Langenbucher, et al., Br. J. Clin. Pharmac, 1985, 19, pp. 151S-162S.
Handsfield Abstract from the 31stInterscience Conference on Antimicrobial Agents & Chemotherapy, 1991.
H. H. Handsfield et al., Sexually Transmitted Diseases, vol. 21(2), pp. 107-111, 1994.
Piero Periti, et al., Clinical Pharmacokinetics, vol. 16, pp. 193-214, 1989.

Affiliated with

Also associated with

Rating

Controlled-release dosage forms of azithromycin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Controlled-release dosage forms of azithromycin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled-release dosage forms of azithromycin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3599667